Trial Profile
A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2017
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SETTLE-extension
- Sponsors Merck Serono
- 16 Dec 2016 New trial record